- Silodosin Intermediate and Preparation Method Therefor
-
Disclosed are a silodosin intermediate and a preparation method thereof. The silodosin intermediate has the structure shown by the formula (A). X is hydrogen or bromide and R1 is hydrogen. The formyl group may be a group having the structure sh
- -
-
Paragraph 0099; 0100; 0101
(2015/06/03)
-
- First asymmetric synthesis of Silodosin through catalytic hydrogenation by using Ir-SIPHOX catalysts
-
An asymmetric synthesis of Silodosin was accomplished in high yield via catalytic hydrogenation of α,β-unsaturated carboxylic acid derivatives by using chiral catalyst Ir-SIPHOX, followed by Curtius rearrangement. Copyright
- Yan, Pu-Cha,Zhang, Xian-Yi,Hu, Xiao-Wei,Zhang, Bin,Zhang, Xiang-Dong,Zhao, Michael,Che, Da-Qing,Li, Yuan-Qiang,Zhou, Qi-Lin
-
p. 1449 - 1451
(2013/04/10)
-
- A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE
-
A method of manufacturing optically pure or optically enriched silodosin of formula I and of its pharmaceutically acceptable salts, in which a secondary amine of general formula II, wherein Bn denotes a phenylmethyl group, substituted or unsubstituted in the benzene ring, e.g. benzyl or 4-methoxybenzyl, or the benzhydryl or trityl group, (a) is N-alkylated with an alkylating agent of general formula III, wherein X denotes a good leaving group, such as a halogen or an alkane sulfonyloxyl group RS020 or an arene SLilfonyloxyl group ArS020, R means an alkyl group with 1 to 4 carbon atoms and Ar is a substituted or unsubstituted phenyl group; (b) the obtained tertiary amine of general formula IV, wherein Bn is as defined above, is hydrogenolyzed with hydrogen on a metal catalyst; (c) and the resulting nitrile of formula V, wherein Bn is as defined above, is hydrolyzed by treatment with alkaline agents; and optionally, (d) additional O-debenzylation of the amide-ether of general formula VI, wherein Bn is as defined above, with dealkylating agents is carried out; and, if desired, the obtained silodosin is transformed to the respective salts by treatment with pharmaceutically acceptable acids.
- -
-
Page/Page column 26
(2012/05/31)
-